BYON4228 + Rituximab clinical trials

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

This study is testing a new discovery medicine called BYON4228, along with an existing medicine called Rituximab. It's for people with a type of blood cancer called lymphoma that hasn't responded well to previous treatments. It aims to see if the new medicine is safe and how well it works.